Each formulation of ZOMIG (zolmitriptan)—ZOMIG® Tablets, ZOMIG-ZMT® (zolmitriptan) and ZOMIG® Nasal Spray—has the speed to deliver a fast headache response, providing
migraine pain relief to today’s patient as she lives her demanding, double-day life at work
and at home.
-
At 45 minutes, response rates were significantly better than with placebo: 26.9% with ZOMIG Tablets 5 mg
vs 17.3% with placebo, increasing rapidly to 62.1% at 2 hours vs 36.0% with placebo1
-
In the same controlled clinical trial, the headache response rate* with ZOMIG Tablets 2.5 mg was significantly
superior to placebo at 45 minutes: 24.5% vs12.4% (P<.001), increasing rapidly to 58.9% at 2 hours
vs 34.6% with placebo(P<.001)1
-
In a separate study, the 2-hour headache response rate* was achieved in 67% of patients receiving
ZOMIG Tablets 5 mg vs 34% for placebo(P<.05)2
* Defined as a reduction in headache severity, from moderate or severe to mild or no pain.
** From a multicenter, randomized, double-blind, placebo-controlled study that included ZOMIG Tablets 5 mg (n=482) vs placebo (n=252) for the treatment of moderate or severe migraine.
-
At 30 minutes, response rates were significantly better than with placebo: 16.5% with ZOMIG-ZMT 5 mg
vs 12.5% with placebo, increasing to 59% at 2 hours vs 30.6% with placebo3
* Defined as a reduction in headache severity, from moderate or severe to mild or no pain.
** From a multicenter, randomized, double-blind, placebo-controlled study that included ZOMIG Tablets 5 mg (n=329) vs placebo (n=341) for the treatment of moderate or severe migraine.
3
>
-
At 10 minutes, response rates were significantly better than with placebo: 15.1% with ZOMIG Nasal Spray 5 mg
vs 9.1% with placebo, increasing rapidly to 64.8% at 2 hours vs 23.9% with placebo4
-
Total symptom relief rate at 1 hour postdose was significantly higher than placebo: 14.5% with ZOMIG Nasal
Spray 5 mg vs 5.1% with placebo(P<.0001)4
* Defined as a reduction in headache severity, from moderate or severe to mild or no pain.
** From a multicenter, randomized,
double-blind, parallel-group trial
(n=1868) with ZOMIG Nasal Spray
5 mg vs placebo, treating up to
2 migraine attacks of moderate or
severe intensity. The primary end
point was headache response at
15 and 30 minutes, 1 and 2 hours
after initial treatment. Secondary
end points included pain-free rates
at all time points and 24-hour
sustained headache response
and pain-free rates.
9